Galectin Therapeutics (NASDAQ:GALT) Receives Daily Media Impact Score of 0.09

News articles about Galectin Therapeutics (NASDAQ:GALT) have trended somewhat positive on Sunday, Accern Sentiment Analysis reports. The research firm rates the sentiment of press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Galectin Therapeutics earned a news sentiment score of 0.09 on Accern’s scale. Accern also gave media coverage about the company an impact score of 45.5845291007937 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

Shares of Galectin Therapeutics (NASDAQ GALT) opened at $5.64 on Friday. Galectin Therapeutics has a 12 month low of $0.94 and a 12 month high of $6.74.

Galectin Therapeutics (NASDAQ:GALT) last released its earnings results on Tuesday, November 7th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.15) by $0.02. analysts expect that Galectin Therapeutics will post -0.52 earnings per share for the current fiscal year.

A number of research firms have recently weighed in on GALT. Roth Capital upped their price target on shares of Galectin Therapeutics from $3.00 to $8.00 and gave the stock a “buy” rating in a research note on Thursday, January 4th. ValuEngine cut shares of Galectin Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Sunday, December 31st. HC Wainwright upped their price target on shares of Galectin Therapeutics from $3.50 to $6.00 and gave the stock a “buy” rating in a research note on Tuesday, November 28th. Zacks Investment Research cut shares of Galectin Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, December 8th. Finally, Seaport Global Securities reissued a “buy” rating and issued a $5.00 price objective on shares of Galectin Therapeutics in a research note on Friday, October 6th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $5.55.

TRADEMARK VIOLATION WARNING: This piece of content was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece of content on another publication, it was illegally copied and republished in violation of United States and international copyright legislation. The legal version of this piece of content can be read at https://www.dispatchtribunal.com/2018/01/21/galectin-therapeutics-galt-getting-somewhat-positive-press-coverage-analysis-finds.html.

About Galectin Therapeutics

Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company’s drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions.

Insider Buying and Selling by Quarter for Galectin Therapeutics (NASDAQ:GALT)

Receive News & Ratings for Galectin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply